SAN DIEGO and PARIS, March 13,
2019 /PRNewswire-PRWeb/ -- WeHealth by Servier, Servier
Group's e-health department, and, CureMatch, a leader in digital
health precision medicine today announced a partnership to jointly
bring the CureMatch platform to oncologists, clinics and hospitals
around the world.
Today, oncologists face the daunting task of understanding
thousands of genomic abnormalities and hundreds of drugs in order
to select treatment options for their cancer patients. Powerful new
technologies like next generation sequencing have uncovered
enormous heterogeneity amongst cancer patients, which tremendously
complicates the decision-making process. "Each cancer is like a
snowflake—complex and unique," says Dr. Razelle Kurzrock, one of the world's leading
precision medicine oncologists and CureMatch Founder. "Their
genetic profile is unique, their tumors are unique, and their
treatment should account for these differences."
"The vision of WeHealth is to offer a precision medicine
approach where the patient is at the center of an individualized
diagnosis and treatment. Our collaboration with CureMatch opens a
large spectrum of potential benefits for the patients and for
oncologists through a better disease management," says Dr.
David Guez, Director General of
WeHealth by Servier.
The WeHealth by Servier/CureMatch partnership will bring the
best of both worlds together in the fight against cancer. "As a
small, innovative company at the leading edge of precision
medicine, we know we have something special to offer, but we don't
have the scale or infrastructure of a large company," says
Bob Manning, CEO of CureMatch. "Our
partnership with WeHealth will provide corporate size and strength
to reach oncologists around the world so much faster than we ever
could on our own. The power of the partnership goes beyond the
power of WeHealth as it encompasses Servier's sales and marketing
expertise, and provides co-development efforts around additional
software development and clinical trial programs."
About WeHealth by Servier
WeHealth by Servier, launched in November
2016 and aiming to improve the daily life of patients and
health professionals' alike using digital, is the e-Health business
unit of the Servier Group. WeHealth by Servier proposes innovative
digital and connected solutions as well as services by making the
most of collected data, to ensure better individual monitoring of
the patient and to better prevent and predict the evolution of the
disease mainly in cardiovascular, neurology, diabetes and oncology
fields. In an open innovative approach, WeHealth by Servier
identifies the most promising start-ups in e-health, in
France and internationally, to
co-develop solutions. In this way, WeHealth by Servier contributes
to the creation of an ecosystem of partners to facilitate and
accelerate the development, industrialization and distribution of
innovations and to make them accessible to the greatest number. For
further information: https://www.wehealthbyservier.com
About Servier
Servier is an international pharmaceutical company governed by a
non-profit foundation, with its headquarters in France (Suresnes). With a strong international
presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000
people worldwide. Entirely independent, the Group reinvests 25% of
its turnover (excluding generic drugs) in research and development
and uses all its profits for development. Corporate growth is
driven by Servier's constant search for innovation in five areas of
excellence: cardiovascular, immune-inflammatory and
neuropsychiatric diseases, cancer and diabetes, as well as by its
activities in high-quality generic drugs. Servier also offers
eHealth solutions beyond drug development. More information:
https://www.servier.com
Press Contacts:
Sonia Marques : media@servier.com –
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau : media@servier.com – Tel. +33 (0)1 55 72 46
16 / + 33 (0) 6 79 56 75 96
Karine Bousseau : media@servier.com
– Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05
About CureMatch
CureMatch, Inc. is a San
Diego-based digital health company focused on personalized
medicine and combination therapy in oncology. CureMatch's Decision
Support System guides oncologists in the selection of cancer drugs
that are customized for individual patients based on their
molecular tumor profile. CureMatch enables oncologists to become
experts in personalized medicine by providing them with actionable
intelligence towards advanced cancer treatment options.
https://www.curematch.com
Press Contact
Bob Manning, CEO
press@curematch.com
(858) 859-2873
SOURCE CureMatch, Inc.